oral medications

1 articles
The Motley FoolThe Motley Fool··Rich Smith

Novo Nordisk Stock Pullback Creates Entry Point for Long-Term GLP-1 Investors

Novo Nordisk stock down 67% offers entry point for long-term investors. Strong GLP-1 market position, attractive valuation metrics, and growth potential despite upcoming competition.
LLYNVOstock valuationdividend stocks